Kamedis and Taro Announce Availability of the Kamedis® Bio-Herbal Dandruff Care System at Walgreens
TEL AVIV, Israel, Feb. 10, 2016 /PRNewswire/ -- Kamedis Inc., a global provider of clinically proven skin care product lines, announced today the launch and retail availability of the Kamedis® Bio-Herbal Dandruff Care system, the world's first therapeutic two-step system to fighting dandruff and seborrheic dermatitis in collaboration with Taro Pharmaceutical Industries Ltd. (Taro), a multinational, science-based pharmaceutical company.
Dandruff is the most common scalp disorder in adolescence and adulthood[i], effecting more than 50 million people in United States[ii]. Both products in the Kamedis Bio-Herbal Dandruff Care system – a scalp lotion and dandruff shampoo – are infused with Botaniplex™, a groundbreaking combination of botanical concentrates and clinically proven active ingredients to visibly reduce scaling and treat the itching at the source, all while nourishing and hydrating the scalp.
"To create a dandruff product that is both effective and gentle on the hair and scalp, we collaborated with a team of dermatologists and researchers who are experts in botanical chemistry. The end result is this new holistic approach to treating dandruff using a two-step regimen that is based on natural ingredients," said Roni Kramer, Chairperson and Chief Executive Officer of Kamedis Inc. "Our philosophies and therapeutic approach to developing botanically-based, clinically proven products will continue to align with the growing consumer demand for natural skin care solutions."
Botaniplex utilizes a proprietary process to purify and concentrate the botanical extracts for maximum efficacy. The system fights dandruff in two ways. The active ingredient, pyrithione zinc, kills the fungus that is the culprit behind many cases of dandruff and seborrheic dermatitis, and the botanical concentrates soothe, hydrate and nourish the hair and scalp, relieving the common symptoms of dandruff. The formulation is also free of parabens, steroids and sodium lauryl sulfates (SLS), making Kamedis both gentle on the scalp and safe to use on color-treated hair.
"We are pleased to collaborate with Kamedis to bring a quality product for dandruff and seborrheic dermatitis – backed by scientific innovation – to consumers in the United States," said John Francis, Taro's Vice President, OTC Sales & Marketing. "As a leading manufacturer and supplier of topical dermatological products, we are committed to delivering meaningful brands that millions of Americans can rely upon."
The Kamedis Bio-Herbal Dandruff Care system is available at Walgreens retail locations nationwide, as well as other select retailers. To learn more and to access in-store coupons, customers may visit www.kamedisdandruff.com.
About Kamedis
Kamedis is a global provider of botanical based, clinically tested and effective skin care products that combine ancient medical wisdom with the knowledge and technology of modern scientific research. Kamedis was created by Chinese medicine therapists specializing in dermatology who envisioned a new approach to treating the symptoms of common skin conditions, such as Atopic Dermatitis/Eczema, Seborrhea, Psoriasis, and Acne. Kamedis utilizes advanced technologies to develop innovative topical therapies, including OTC Healthcare products, barrier creams, and Derma-cosmetic formulations. Products are available in the United States, Europe and Asia. More information about Kamedis is available at www.kamedis-usa.com or (855) 526-3347.
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.
Contact:
Media Relations
Rachel Kessler
917.660.0608
[email protected]
[i] R Dawber, Isolated dandruff, Martin Dunitz (1994); R Dawber, Shampoos: Scientific basis and clinical aspects, The Royal Society of Medicine Press International Congress and Symposium Series 216 (1995); AB Ackerman, AM Kligman, in J Society of Cosmetic Chemists 20 81-101 (1969).
[ii] International Journal of Trichology; A New Postulate on Two Stages of Dandruff: A Clinical Perspective Frederick Manuel and S Ranganathan; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129121/
SOURCE Kamedis Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article